Airbus A380 Cracks,...
Health Care: Drugs
Pluristem Therapeutic (PSTI: NASDAQ)
$2.63 0.04 | 1.54%
02/08/12 - 03:59 PM ET
43.14K / 86.40K
Vol / Avg. Vol:2.63 / 2.59
Open / Prev. Close:2.59 - 2.64
Today's Range:1.98 - 3.66
52 Wk Range:5.62%
Performance YTD:TheStreet Rating:
Portfolios with PSTI
- Portfolio NameUser Type
Latest PSTI Headlines from TheStreet
- Pluristem Therapeutics And NYU Medical Center Partner To Study Use Of PLX Cells In Treatment Of Diabetic Foot Ulcers 03.15.11 | 07:03 am
- Pluristem Therapeutics To Present At Leading Investor Conferences 03.07.11 | 07:03 am
- Sonus Networks, Novavax: Small-Cap Winner 03.01.11 | 12:03 pm
- Positive Pre-Clinical Data From Muscle Injury Study Moves Pluristem Toward Second Multi-Billion Dollar Clinical Indication 03.01.11 | 07:03 am
- Pluristem Announces Closing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock 02.01.11 | 10:02 am
- Pluristem Announces Pricing Of Public Offering Of Common Stock And Warrants To Purchase Common Stock 01.27.11 | 09:01 am
- Pluristem Announces Proposed Public Offering Of Common Stock And Warrants To Purchase Common Stock 01.26.11 | 04:01 pm
- AK Steel, Brinker: Small-Cap Winners 01.25.11 | 03:01 pm
- Sterling, Ener1: Small-Cap Winners 01.18.11 | 12:01 pm
- Pluristem On Track To Proceed To A Phase II/III Clinical Trial In Critical Limb Ischemia (CLI) Under A Joint FDA-EMA Protocol, And A Phase II Clinical Trial In Intermittent Claudication (IC) 01.18.11 | 07:01 am
Press Releases for PSTI
- Pluristem Therapeutics Raises Approximately $5 Million In Private Placement Of Common Stock - Business Wire 10.12.10 | 08:10 am
- Data From Clinical Trials Show Pluristem’s Placenta-Derived Cell Therapy Is Safe And Improves Quality Of Life And Efficacy Measurements In Patients With Critical Limb Ischemia - Business Wire 09.14.10 | 08:09 am
- Pluristem’s Placenta Derived Cells Chosen By European Commission’s Seventh Framework Program (FP7) Study For Treatment Of Diastolic Heart Failure (DHF) In Type 2 Diabetic Patients - Business Wire 08.30.10 | 08:08 am
- Pluristem's PLX Cells Found To Be Effective In Treating Neuropathic And Inflammatory Pain - Business Wire 08.09.10 | 08:08 am
- Pluristem Appoints Diabetic Neuropathy And Vascular Disease Expert, Dr. Aristidis Veves, To Its Scientific Advisory Board - Business Wire 08.04.10 | 08:08 am
- Pluristem Is Advancing Toward Two Phase IIb Clinical Trials For Treatment Of Critical Limb Ischemia And Moderate-Severe Claudication - Business Wire 06.28.10 | 08:06 am
- Pluristem’s Off-The-Shelf Placenta-Derived Cell Therapies - The Focus Of Presentations At Upcoming Investor And Medical Conferences - Business Wire 05.20.10 | 08:05 am
Partner Headlines for PSTI
- Company News for July 12, 2011 - Corporate Summary - Zacks 07.12.11 | 10:07 am
- Pluristem Therapeutics Pops on Licensing Pact - Benzinga 06.20.11 | 04:06 pm
- Pluristem Therapeutics Ticks Higher On CNBC Chatter (PSTI) - Benzinga 04.05.11 | 01:04 pm
- UPDATE 1-Pluristem plans to raise $35.8 mln on Nasdaq - Reuters 01.27.11 | 11:01 am
- UPDATE 1-Pluristem stem cell drug approved for advanced trial - Reuters 01.18.11 | 07:01 am
- Pluristem to dual list in Tel Aviv, eyes fund raising - Reuters 12.15.10 | 07:12 am
- Six Reasons to Like Pluristem Therapeutics - Seeking Alpha 10.13.10 | 08:10 am
- PAD Awareness Month Brings Cardiovascular Companies to the Forefront - Seeking Alpha 09.16.10 | 09:09 am
- Pluristem Pops on Cell Therapy Data (PSTI) - Benzinga 09.14.10 | 09:09 am
- Pluristem sees positive result for stem cell therapy - Reuters 09.14.10 | 08:09 am
